640 related articles for article (PubMed ID: 25390017)
1. Roles of oxidative stress, adiponectin, and nuclear hormone receptors in obesity-associated insulin resistance and cardiovascular risk.
Matsuda M; Shimomura I
Horm Mol Biol Clin Investig; 2014 Aug; 19(2):75-88. PubMed ID: 25390017
[TBL] [Abstract][Full Text] [Related]
2. Roles of adiponectin and oxidative stress in obesity-associated metabolic and cardiovascular diseases.
Matsuda M; Shimomura I
Rev Endocr Metab Disord; 2014 Mar; 15(1):1-10. PubMed ID: 24026768
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the relationship between obesity, inflammation, and insulin resistance.
Bastard JP; Maachi M; Lagathu C; Kim MJ; Caron M; Vidal H; Capeau J; Feve B
Eur Cytokine Netw; 2006 Mar; 17(1):4-12. PubMed ID: 16613757
[TBL] [Abstract][Full Text] [Related]
4. Adiponectin and its gene variants as risk factors for insulin resistance, the metabolic syndrome and cardiovascular disease.
Gable DR; Hurel SJ; Humphries SE
Atherosclerosis; 2006 Oct; 188(2):231-44. PubMed ID: 16581078
[TBL] [Abstract][Full Text] [Related]
5. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases.
Yamauchi T; Kadowaki T
Int J Obes (Lond); 2008 Dec; 32 Suppl 7():S13-8. PubMed ID: 19136982
[TBL] [Abstract][Full Text] [Related]
6. Modulation of adiponectin as a potential therapeutic strategy.
Lim S; Quon MJ; Koh KK
Atherosclerosis; 2014 Apr; 233(2):721-728. PubMed ID: 24603219
[TBL] [Abstract][Full Text] [Related]
7. The metabolic syndrome: metabolic changes with vascular consequences.
Wassink AM; Olijhoek JK; Visseren FL
Eur J Clin Invest; 2007 Jan; 37(1):8-17. PubMed ID: 17181562
[TBL] [Abstract][Full Text] [Related]
8. Oxidative stress as pathogenesis of cardiovascular risk associated with metabolic syndrome.
Otani H
Antioxid Redox Signal; 2011 Oct; 15(7):1911-26. PubMed ID: 21126197
[TBL] [Abstract][Full Text] [Related]
9. Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance.
Højlund K
Dan Med J; 2014 Jul; 61(7):B4890. PubMed ID: 25123125
[TBL] [Abstract][Full Text] [Related]
10. Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases.
Tilg H; Moschen AR
Clin Sci (Lond); 2008 Feb; 114(4):275-88. PubMed ID: 18194136
[TBL] [Abstract][Full Text] [Related]
11. Dietary regulation of nuclear receptors in obesity-related metabolic syndrome.
Kawada T; Goto T; Hirai S; Kang MS; Uemura T; Yu R; Takahashi N
Asia Pac J Clin Nutr; 2008; 17 Suppl 1():126-30. PubMed ID: 18296319
[TBL] [Abstract][Full Text] [Related]
12. Skeletal muscle and nuclear hormone receptors: implications for cardiovascular and metabolic disease.
Smith AG; Muscat GE
Int J Biochem Cell Biol; 2005 Oct; 37(10):2047-63. PubMed ID: 15922648
[TBL] [Abstract][Full Text] [Related]
13. Adipose inflammation, insulin resistance, and cardiovascular disease.
Shah A; Mehta N; Reilly MP
JPEN J Parenter Enteral Nutr; 2008; 32(6):638-44. PubMed ID: 18974244
[TBL] [Abstract][Full Text] [Related]
14. The role of adiponectin in obesity, diabetes, and cardiovascular disease.
Kawano J; Arora R
J Cardiometab Syndr; 2009; 4(1):44-9. PubMed ID: 19245516
[TBL] [Abstract][Full Text] [Related]
15. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease.
Lara-Castro C; Fu Y; Chung BH; Garvey WT
Curr Opin Lipidol; 2007 Jun; 18(3):263-70. PubMed ID: 17495599
[TBL] [Abstract][Full Text] [Related]
16. Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease.
Matsuzawa Y
Nat Clin Pract Cardiovasc Med; 2006 Jan; 3(1):35-42. PubMed ID: 16391616
[TBL] [Abstract][Full Text] [Related]
17. Type 2 diabetes and cardiovascular disease: getting to the fat of the matter.
Goralski KB; Sinal CJ
Can J Physiol Pharmacol; 2007 Jan; 85(1):113-32. PubMed ID: 17487251
[TBL] [Abstract][Full Text] [Related]
18. Obesity and cardiovascular disease: role of adipose tissue, inflammation, and the renin-angiotensin-aldosterone system.
Lastra G; Sowers JR
Horm Mol Biol Clin Investig; 2013 Sep; 15(2):49-57. PubMed ID: 25436732
[TBL] [Abstract][Full Text] [Related]
19. Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice.
Verreth W; De Keyzer D; Pelat M; Verhamme P; Ganame J; Bielicki JK; Mertens A; Quarck R; Benhabilès N; Marguerie G; Mackness B; Mackness M; Ninio E; Herregods MC; Balligand JL; Holvoet P
Circulation; 2004 Nov; 110(20):3259-69. PubMed ID: 15533870
[TBL] [Abstract][Full Text] [Related]
20. Adiponectin, obesity, and cardiovascular disease.
Fasshauer M; Paschke R; Stumvoll M
Biochimie; 2004 Nov; 86(11):779-84. PubMed ID: 15589686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
